EXEDRA (733296)

  https://cordis.europa.eu/project/id/733296

  Horizon 2020 (2014-2020)

  EXpansion of the European Joint Programming Initiative on Drug Resistance to Antimicrobials

  Towards globalisation of the Joint Programming Initiative on Antimicrobial resistance (SC1-HCO-04-2016)

 

  2017-01-01 Start Date (YY-MM-DD)

  2021-12-31 End Date (YY-MM-DD)

  € 2,231,438 Total Cost

  Description

EXEDRA, an EXpansion of the European Joint Programming Initiative on Drug Resistance to Antimicrobials, will build on, and further support the structure and activities of JPIAMR to address the two major objectives of HCO-04-2016 topic: extending JPIAMR globally and creating a long-term sustainable structure for future expansion and governance which will coordinate national funding and collaborative actions supporting the implementation of the JPIAMR Strategic Research Agenda (SRA). JPIAMR EXEDRA will be the second Coordinated Support Action (CSA) for this Joint Programming Initiative (JPI) and essentially build on the work of the first CSA (JPIAMR), which ended February 2016. It will provide a strong support structure for the JPIAMR during the forthcoming implementation and expansion phaseby maintaining a continuity between the objectives, tasks and Work Packages of EXEDRA and JPIAMR. Support facilitated by the CSA EXEDRA will ensure that the ethos of joint programming in the area antimicrobial drug resistance becoming embedded within JPIAMR member’s research and innovation policies and programmes. EXEDRA will have the following work packages: WP1 Management and coordination; WP2 Strategy, governance, and long term sustainability; WP3 Internationalisation and capacity extension; WP4 Alignment with policy and industry; WP5 Research alignment; WP6 Communication, dissemination, and advocacy. EXEDRA will significantly contribute to the delivery of the JPIAMR SRA combined with the JPI-EC-AMR effort and the experience of the JPIAMR members. EXEDRA (and the JPIAMR) will support transnational cooperation to to pool substantial and long-term research funding and serve to complement other initiatives in the AMR area. It will create momentum with the potential to move the frontiers forward and offer new opportunities for industry, new tools for society, and new evidence-based data for policy makers, which will inspire other necessary initiatives.

  Complicit Organisations

1 Israeli organisation participates in EXEDRA.